-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Product Insights
IgA Nephropathy (Berger's Disease): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2025" provides an overview of IgA Nephropathy (Berger's Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
IgA Nephropathy (Berger's Disease) - Drugs In Development, 2024
Empower your strategies with our IgA Nephropathy (Berger's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. IgA nephropathy, also known as Berger's disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.